Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amlodipine
Drug ID BADD_D00121
Description Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers [A175327]. Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure [A175321]. The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label].
Indications and Usage For the treatment of hypertension and chronic stable angina.
Marketing Status Prescription; Discontinued
ATC Code C08CA01
DrugBank ID DB00381
KEGG ID D07450
MeSH ID D017311
PubChem ID 2162
TTD Drug ID D08JIV
NDC Product Code 52652-5001; 46287-035
Synonyms Amlodipine | Amlodipine, (+-)-Isomer | Amlodipine Besylate | Amlodipine, (+-)-Isomer, Maleate (1:1) | Amlodipine, (S)-Isomer, Maleate (1:1) | Amlodis | Astudal | Norvasc | Istin | Amlor | Amlodipine Maleate | Amlodipine Maleate (1:1) | Amlodipine, (R)-Isomer
Chemical Information
Molecular Formula C20H25ClN2O5
CAS Registry Number 88150-42-9
SMILES CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lymphatic disorder01.09.01.003--Not Available
Pruritus generalised23.03.12.0030.000046%Not Available
Musculoskeletal stiffness15.03.01.005--Not Available
Protein urine present13.13.02.0060.000031%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.000046%Not Available
Affect lability19.04.01.001--Not Available
Haemorrhage24.07.01.002--Not Available
Body height decreased13.15.01.0290.000031%Not Available
Paraesthesia oral17.02.06.008; 07.05.03.0030.000031%Not Available
Toxic skin eruption23.03.05.003; 10.01.01.0080.000046%Not Available
Troponin increased13.04.01.0040.000061%Not Available
Hypoperfusion24.06.02.0190.000031%Not Available
Angiopathy24.03.02.007--Not Available
Urine output decreased13.13.03.0010.000107%
Urine output increased13.13.03.002--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Prostate cancer16.25.01.001; 21.04.02.0020.000008%Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Embolism24.01.01.0090.000008%
Lung infection22.07.01.008; 11.01.09.0080.000031%
Ischaemic stroke24.04.06.010; 17.08.01.018--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Sudden hearing loss04.02.01.0090.000031%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
The 15th Page    First    Pre   15 16 17    Next   Last    Total 17 Pages